PLoS One by Puttkammer, Nancy et al.
Development of an Electronic Medical Record Based
Alert for Risk of HIV Treatment Failure in a Low-Resource
Setting
Nancy Puttkammer1,2*, Steven Zeliadt2, Jean Gabriel Balan3, Janet Baseman4, Rodney Destiné3,
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Abstract
Background: The adoption of electronic medical record systems in resource-limited settings can help clinicians monitor
patients’ adherence to HIV antiretroviral therapy (ART) and identify patients at risk of future ART failure, allowing resources
to be targeted to those most at risk.
Methods: Among adult patients enrolled on ART from 2005–2013 at two large, public-sector hospitals in Haiti, ART failure
was assessed after 6–12 months on treatment, based on the World Health Organization’s immunologic and clinical criteria.
We identified models for predicting ART failure based on ART adherence measures and other patient characteristics. We
assessed performance of candidate models using area under the receiver operating curve, and validated results using a
randomly-split data sample. The selected prediction model was used to generate a risk score, and its ability to differentiate
ART failure risk over a 42-month follow-up period was tested using stratified Kaplan Meier survival curves.
Results: Among 923 patients with CD4 results available during the period 6–12 months after ART initiation, 196 (21.2%) met
ART failure criteria. The pharmacy-based proportion of days covered (PDC) measure performed best among five possible ART
adherence measures at predicting ART failure. Average PDC during the first 6 months on ART was 79.0% among cases of
ART failure and 88.6% among cases of non-failure (p,0.01). When additional information including sex, baseline CD4, and
duration of enrollment in HIV care prior to ART initiation were added to PDC, the risk score differentiated between those
who did and did not meet failure criteria over 42 months following ART initiation.
Conclusions: Pharmacy data are most useful for new ART adherence alerts within iSanté. Such alerts offer potential to help
clinicians identify patients at high risk of ART failure so that they can be targeted with adherence support interventions,
before ART failure occurs.
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Introduction
HIV antiretroviral therapy (ART) requires adherence levels of
.90% in order to optimize therapeutic benefit [1,2]. Patients with
lesser adherence run the risk of incomplete HIV viral suppression
and developing resistance to ART medications. In resource-
limited settings, the high cost and limited availability of second-line
ART regimens make it critical to minimize ART therapeutic
failures with first-line regimens.
Early identification of gaps in ART adherence can help prevent
ART failure. However, measuring ART adherence is a challenge
[3]. Many of the techniques considered to be most valid, such as
examination of drug concentrations in tissue samples, medication
electronic monitoring system caps, and unannounced pill counts
during home visits, are costly to implement and impractical in
resource-limited settings [4,5]. Self-reported measures gathered on
a routine basis during clinic visits are more practical, but may be
biased due to poor recall or social desirability [1,6,7,8]. Pharmacy-
based adherence measures derived from ART dispensing data can
also be practical in resource-limited settings, depending on
availability and quality of data [8,9].
The adoption of electronic medical record systems in resource-
limited settings can help clinicians monitor patients’ ART
adherence and identify patients at risk of future ART failure,
allowing resources to be targeted to those most at risk. This study
used data from the iSanté electronic medical record system in
Haiti to develop and validate a prediction model for risk of ART
failure, based upon self-reported and pharmacy-based adherence
measures as well as other patient demographic and clinical data.
Materials and Methods
Study Setting and Patient Population
The study cohort included adult (age $15 years) HIV patients
from Hôpital St. Michel in Jacmel (HSM) and Hôpital St. Antoine
in Jérémie (HSA) who initiated a life-long ART regimen between
January 1, 2005 – June 30, 2013. ART regimens used for
prevention of mother-to-child HIV transmission (PMTCT) or
other prophylaxis were not considered to be life-long regimens and
were excluded from the analysis (although patients using ART for
prophylaxis had the opportunity to enter the analysis later, upon
initiating a life-long regimen).
Both hospitals provide primary and secondary levels of service
and serve as the main referral hospitals in their respective
departments, which are rural and mountainous regions of Haiti.
Adult HIV prevalence is estimated to be 2.1% in the region served
by HSM and 1.5% in the region served by HSA [10]. Both
facilities began their ART programs in early 2005, and by mid-
2013 had together enrolled 2,510 patients on ART.
Data Source
All study data came from the consolidated server for the Haitian
Ministry of Public Health and Population’s (MSPP) iSanté
electronic medical record (EMR) system. The iSanté system is
used in more than 100 health care facilities and contains
longitudinal health records on approximately 300,000 patients,
including approximately half of the 42,000 Haitians receiving
ART in 2012 [11,12,13].
iSanté was first deployed in Haiti in April 2005, based upon
standardized HIV clinical care encounter forms, laboratory forms,
and pharmacy forms originally validated and disseminated by the
MSPP in October 2004. Over time, the MSPP added encounter
forms for ancillary HIV services like ART adherence assessment,
counseling, and home visits. At the facilities, use of the iSanté
EMR system evolved from retrospective data entry of paper forms
toward point-of-care use at both hospitals. The EMR interface
closely matches the format and content of the paper forms, with an
emphasis on structured data elements rather than free text. While
the electronic system contains data validation rules and warnings,
it places few hard constraints on data entry and has few mandatory
data elements.
First use of iSanté began in March 2006 at HSA and April 2006
at HSM, and the system was used to retrospectively capture data
for ART patients who initiated treatment as early as January 2005
at HSA and March 2005 at HSM. The ART adherence
assessment form was added to the system in February 2008.
Data obtained from the consolidated data repository were de-
identified and the study close date was June 30, 2013.
ART Adherence Measures
We explored five types of adherence measures using iSanté
data. The first three were pharmacy-based measures: 1) medica-
tion possession ratio (MPR), or total quantity of medication of any
type dispensed divided by the number of days in the calendar
period; 2) proportion of days covered (PDC), or the proportion of
days during the period which are covered by the most recently
prescribed medication (a more conservative estimate of adherence
than MPR since it excludes left-over medication stockpiled from
prior prescriptions); and 3) timely visit ratio (TVR), or the
proportion of pharmacy refills collected no more than 2 days after
the expected refill due date. Our procedures for calculating MPR
and PDC used dispense dates and the number of days of
medication dispensed, based on standard definitions [14,15] and
methods of calculation [16]. Since MPR can exceed 100% when
patients pick up refills before exhausting earlier medication
supplies, we truncated our measure of MPR measure at 100%
to represent maximum possible adherence. The remaining two
were self-reported measures collected by clinicians or pharmacists
using the standard adherence assessment form during regular
clinical visits. These were: 4) the average level of medications taken
during the past 30 days, based on a visual analogue scale (VAS);
and 5) the proportion of adherence assessments where patients
reported no missed doses during the last 3 days (%NoMD). The
VAS used a standard, validated instrument translated from
English [17]. Baseline adherence measures during the first 6
months on ART were used in the analyses.
Study Outcome
The outcome of interest was ART failure, based on World
Health Organization (WHO) immunologic and clinical criteria. A
patient was considered to have failed ART if they met any of the
following criteria: 1) fall in CD4 cell count to the baseline level or
below; 2) fall in CD4 to below 50% of the peak value following
ART initiation; 3) persistent CD4 cell count of ,100 cells/ml; or 4)
onset of a new WHO stage IV diagnosis not reflective of immune
reconstitution syndrome [18]. According to Haitian national
EMR-Based Alert for HIV Treatment Failure
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treatment guidelines, presence of any of these criteria after 6
months of ART use can trigger consideration of a switch to a
second-line ART regimen [19]. Clinical diagnosis data within
iSanté were fairly incomplete, and could not be used in absence of
CD4 data to differentiate ART failures from non-failures. We
restricted the primary and secondary analyses to patients with both
baseline and follow-up CD4 measures and allowed this group to
meet the ART failure definition based on either WHO immuno-
logic or clinical criteria.
Our primary analysis considered ART failure outcomes
observed during months 7–12 following ART initiation, while
our secondary analysis considered ART failure outcomes observed
during months 7–42 following ART initiation (Figure 1). The
baseline CD4 level was the measure occurring closest in time to
the ART start date, during the period from 180 days before ART
initiation to 7 days after ART initiation.
Covariates
Covariates considered in the analysis were: hospital facility,
gender, marital status, age at ART initiation, location of residence
relative to the hospital, type of initial ART regimen, duration of
enrollment in HIV care prior to ART initiation, year of ART
initiation, baseline CD4 cell count, baseline body mass index
(BMI), number of ART adherence assessments conducted during
the first 6 months on treatment, and whether any ART adherence
assessment was done by a clinician. We had data available on
commune of residence, so location of residence was grouped by
residence in: 1) the same commune as the hospital; 2) an adjacent
commune bordering the commune of the hospital; or (3) a non-
adjacent commune.
Data Validation and Cleaning
We conducted a data validation exercise to assess the
concordance between information in the EMR and information
on paper-based forms at the two hospitals. Among a random
sample of 200 ART patients, concordance of data exceeded 90%
for date of ART enrollment and exceeded 95% for year of birth,
gender, CD4 value, ART medication prescribed, and number of
days of medication prescribed [20].
We applied a limited set of data cleaning rules to the electronic
data, suitable for eventual use within an automated algorithm to
be run in real-time against patient data within the live iSanté
database. These rules were applied to patient registration dates,
visit dates, medication dispense dates, patient BMI, and patient
ages. The rules included logic for selecting dates when implausible
date relationships existed (i.e. when a visit date fell before a
registration date), excluded observations of weight or height which
fell outside of humanly plausible bounds, and imputed patient ages
when day or month of birth was missing (rules available upon
request from the corresponding author).
The minimum quantity of medication dispensed for any single
drug within a multi-drug regimen was used to calculate ART
Figure 1. Flow Chart for Participants in the 12-Month and 42-Month Analyses.
doi:10.1371/journal.pone.0112261.g001
EMR-Based Alert for HIV Treatment Failure
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e112261
regimen refill due dates. For dispenses with missing quantities of
medication dispensed, the between-visit time interval was excluded
from both the numerator and denominator of the pharmacy-based
adherence measures. Covariates with missing data were treated as
categorical variables with a missing data category.
Statistical methods
Descriptive statistics. We examined patient characteristics
and baseline ART adherence measures among those with and
without ART failure observed during the 7–12 months following
ART initiation, and compared observed values between the two
groups using Pearson’s Chi-square test, Student’s t-test, or the
Wilcoxon rank sum test for continuous variables with skewed
distributions. We also compared patient characteristics and
baseline adherence among patients included vs. excluded from
our analyses, to identify any selection issues.
Primary analysis, Step 1: Selection of adherence
measure. First, we assessed how well each of the five baseline
adherence measures predicted ART failure by 12 months. Patients
retained within the 12-month analysis had at least 182 days of
study follow-up after ART initiation and had a follow up CD4
measure taken from 182–365 days after ART initiation (n = 923,
see Figure 1). Logistic regression models using continuous forms
of each measure were used to test prognostic accuracy, using the
area under the receiver operating characteristic curve (AUC)
[21,22]. The best performing measure was considered to be the
measure which offered the highest AUC.
Primary analysis, Step 2: Selection of patient
characteristics. Next, we considered enrichment of the pre-
diction model using additional covariates beyond the selected
adherence measure. Patients with 12-month outcomes were split
randomly into 50:50 derivation and validation sub-samples [23]. A
forward stepwise selection procedure, using the Akaike Informa-
tion Criterion (AIC), was used to identify a robust yet parsimo-
nious prediction model in the derivation sub-sample [24]. The
performance of the resulting prediction model was then assessed in
the validation sub-sample. For continuous covariates retained in
the model following the stepwise procedure, we categorized
continuous covariates into deciles to identify the dichotomous level
of the covariate at which predicted risk increased markedly, and
then compared performance of continuous and binary forms of the
covariates to assess whether performance degraded with simpli-
fied, binary versions of the covariates. We used dichotomous
versions of each covariate in the final prediction model.
Primary analysis, Step 3: Formulation of a risk score and
risk groupings. A risk score, taking into account the relative
weight of each covariate, was constructed by multiplying the
estimated coefficients from the logistic model by 10 and rounding
to the nearest decimal place and then multiplying this quantity by
the covariate value [25,26,27]. We assessed the performance and
calibration of the risk score in the validation sample, using the
AUC and the Hosmer-Lemeshow goodness of fit test [28]. Finally,
we created a risk grouping with low, medium and high categories
based on tertiles of the risk score distribution, and examined
performance and calibration of the risk groupings using similar
methods.
Secondary analysis: ART failure by 42 months. Our goal
in this secondary analysis was to further validate the formulation of
the risk score and risk groupings and to assess their performance in
predicting ART failure over a longer time frame, through 42
months following ART initiation. For this analysis, we used time-
to-event, or survival analysis, methods [29]. Patients retained
within the 42-month analysis had at least 365 days of study follow-
up after ART initiation (n = 1,302, see Figure 1). Each patient
contributed up to seven 6-month periods to the analysis and time
to first ART failure was the right-censored outcome. Patients were
followed from the date of ART initiation until the period of ART
failure, the period prior to the study close date, or the period
where loss to follow-up occurred, whichever was first. Loss to
follow-up was defined as having 180 days pass with no clinical
encounter.
To compare the performance of the adherence measures in the
survival analysis framework, we created standardized versions of
the baseline adherence measures using z-scores. Then we assessed
each measure’s ability to predict ART failure in separate Cox
regressions. The standardized adherence measure with the largest
magnitude regression coefficient was taken to offer strongest
prediction capability. Next, we applied the risk score and risk
groupings derived in the primary analysis to the survival data. We
stratified the Kaplan-Meier survival curves by risk groupings and
used the log-rank test to assess differences in the survival curves
across the groups over the extended 42-month time frame.
Sensitivity analyses. We explored the robustness of the
results in the context of incomplete baseline CD4 cell count data.
Specifically, we relaxed the requirement for a baseline CD4
measure to be available, assuming that these patients could still be
observed to fail based on WHO criteria 2–4. All the steps in the
primary and secondary analysis were repeated; however, baseline
CD4 was modeled with a missing value category.
Ethics Statement
The study protocol was reviewed by the University of
Washington and received a human subjects exemption based
upon use of existing de-identified patient data. It was also reviewed
by the US Centers for Disease Control and Prevention and
approved as a non-research program evaluation, and was reviewed
and approved by the Haiti National Bioethics Committee.
Results
Analysis Cohorts and Availability of Adherence Data
There were 923 patients within the primary analysis of ART
failure at 12 months (Figure 1). More than half of patients in the
original cohort lacked baseline CD4 results, follow-up CD4 results,
or both, and were excluded from the analysis (n = 1,587). An
additional 441 patients were able to be included in the secondary
analysis of ART failure by 42 months, based upon having a follow-
up CD4 available after 12 months (Figure 1). Patient character-
istics are shown in Tables 1–2.
Pharmacy-based adherence data were more readily available
than self-reported adherence data, during the first 6 months on
ART for all patients in the study (Table 3). While less than 5% of
patients lacked pharmacy-based adherence measures, 40% of
patients lacked self-reported adherence measures. Among patients
enrolled on ART after the adherence assessment form was
introduced in February 2008 for collecting self-reported measures,
17.5% lacked these measures during the first 6 months on ART.
ART medications were dispensed on average for 40.8 days (IQR:
32–50 days), indicating that dispensing data were generally
sufficiently frequent to calculate pharmacy-based adherence
measures on a 3–6 month basis.
Adherence Levels
In the overall cohort of 2,510 patients, mean adherence within
the first 6 months was estimated to be highest based on the VAS
measure (91.4%), followed by MPR (77.0%), TVR (76.1%),
%NoMD (76.0%), and finally PDC (75.1%) (Figure 2). MPR and
PDC were lower among the 1,587 patients who were excluded
EMR-Based Alert for HIV Treatment Failure
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from the primary 12-month analysis than among the 923 patients
who were included. Patients with no self-reported measures had
markedly lower pharmacy-based adherence measures than those
with self-reported measures available. Among those enrolled on
ART after the introduction of the adherence assessment form and
included in our primary analysis (n = 643), mean PDC was 88.7%
among those with a self-reported measure but only 66.2% among
those without one (p,0.001 by t-test). In other words, those who
never provided self-reported adherence data tended to have
poorer adherence as estimated by pharmacy data.
Primary Analysis: ART failure by 12 months
Among the patients included in the primary analysis (n = 923),
196 (21.2%) met ART failure criteria by 12 months. Of the failure
cases, 75% had a follow-up CD4 below the baseline value, 19%
had a follow-up CD4 below 100 cells/ml, 5% met both of these
CD4 criteria, and ,1% had a new stage IV clinical diagnosis.
ART failure was more typical among male patients (p = 0.04),
those who started ART in 2005–06 (p,0.01), those with higher
baseline CD4 level (p,0.001), and those with no adherence
assessments conducted during the first 6 months on treatment
(p = 0.03) (Tables 1–2).
Table 1. Patient Characteristics (Categorical Variables).
Full Study Cohort Primary Analysis Failure cases
(n = 2,510) (n = 923) (primary analysis)
n % n % n %
Site
HSA Jérémie 1,302 51.9% 453 49.1% 100/453 22.1%
HSM Jacmel 1,208 48.1% 470 50.9% 96/470 20.4%
Sexa
Male 1,066 42.5% 382 41.4% 94/382 24.6%
Female 1,444 57.5% 541 58.6% 102/541 18.9%
Marital status
Single 624 24.9% 227 24.6% 49/227 21.6%
Married/cohabitating 1,451 57.8% 539 58.4% 116/539 21.5%
Widowed/separated 343 13.7% 121 13.1% 21/121 17.4%
Unknown 92 3.7% 36 3.9% 10/36 27.8%
ART start yearb
2005–06 314 12.5% 135 14.6% 42/135 31.1%
2007–08 680 27.1% 296 32.1% 58/296 19.6%
2009–10 668 26.6% 225 24.4% 37/225 16.4%
2011–12 848 33.8% 267 28.9% 59/267 22.1%
Proximity of residence to site
Same commune 861 34.3% 355 38.5% 77/355 21.7%
Adjacent commune 401 16.0% 124 13.4% 29/124 23.4%
Non-adjacent commune 1,205 48.0% 431 46.7% 88/431 20.4%
Missing 43 1.7% 13 1.4% 13-Feb 15.4%
ART starting regimen
AZT-3TC-EFV 1,223 48.7% 464 50.3% 111/464 23.9%
AZT-3TC-NVP 725 28.9% 293 31.7% 56/293 19.1%
Other standard 509 20.3% 143 15.5% 21/143 14.7%
Non-standard 53 2.1% 23 2.5% 8/23 34.8%
Number of adherence assessments (months 1–6)a
None 1,172 46.7% 340 36.8% 88/340 25.9%
One 156 6.2% 62 6.7% 10/62 16.1%
2 or more 1,182 47.1% 521 56.4% 98/521 18.8%
Any adherence assessment by clinician (months 1–6)
No 1,846 73.5% 641 69.4% 138/641 21.5%
Yes 664 26.5% 282 30.6% 58/282 20.6%
AZT = zidovudine, 3TC = lamivudine, EFV = efavirenz, NVP = nevirapine.
Chi-square test p-values for difference in failure proportions by group, among patients included in the primary analysis: ap,.05,
bp,0.01.
doi:10.1371/journal.pone.0112261.t001
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The MPR and PDC measures differentiated cases of ART
failure from non-failure, with non-overlapping 95% confidence
intervals for mean measures in these two groups (Figure 2). Mean
MPR and PDC levels were approximately nine percentage points
lower among cases of failure vs. non-failure (p,0.001 for each).
The mean TVR measure had slightly overlapping 95% confidence
intervals in the ART failure vs. non-failure groups. In contrast, the
self-reported measures did not differentiate the two groups and the
95% confidence intervals for the mean measures were largely
overlapping.
In the first step of identifying a robust prediction model – that of
selecting the best-performing adherence measure from among the
five available measures – PDC demonstrated the best performance
(AUC = 0.61; 95% CI: 0.56–0.66) (Table 4). In the second step,
the stepwise covariate selection procedure conducted in the
training dataset revealed several significant predictors of ART
failure over and above PDC. These were male sex, higher baseline
CD4 level, and lower duration of enrollment in HIV care prior to
starting ART (‘‘pre-ART duration’’). The prediction model with
both baseline adherence and these other patient characteristics
performed better than models with only adherence or with only
patient characteristics in the validation dataset (Table 5). The
covariates for age, marital status, hospital site, proximity of
residence, ART start year, initial ART regimen, baseline BMI,
number of adherence assessments, and having any adherence
assessment done by a clinician all failed to improve the AIC and
were dropped from the prediction model. Predicted risk jumped
with PDC,80%, with baseline CD4 values of .250 cells/ml, and
with pre-ART duration of less than 160 days (data not shown).
A simplified prediction model using binary versions of each
covariate performed as well as a model using continuous versions
of covariates (Table 5). The risk score had possible values 0–32.5
and followed the equation:
Risk Score = 7.7(pdc#0.80) +9.6(cd4$250) +8.9(duration#
160) +6.3(male sex)
Grouping the risk score into tertiles for high, medium, and low
risk also resulted in predictive discrimination in the validation
sample, with an AUC of 0.63 (95% CI: 0.58–0.68). The
proportion of patients experiencing ART failure by 12 months
was 10.1% in the low risk group, 14.4% in the medium risk group,
and 28.7% in the high risk group. The odds of ART failure at 12
months was 1.5 times higher for patients in the medium risk group
(OR = 1.50; 95% CI: 0.66–3.40, p = 0.37) and 3.6 times higher for
patients in the high risk group (OR = 3.58; 95% CI: 1.76–7.30,
p,0.0001), compared to those in the low risk group (results not
shown).
The implications of using each different risk grouping as a cut-
off for a positive ‘‘risk test’’ are shown in Table 6. Using the low
group as the cut-off would treat 100% patients as positive for the
risk test and would be equivalent to no test. Using the medium
group as the cut-off would identify approximately 75% of patients
as positive for the risk test, while using the high group as the cut-off
would classify approximately 50% of patients as positive for the
risk test. The sensitivities, specificities, positive and negative
predictive values for each risk test strategy, derived from the
validation sample of the 12-month outcome study, are shown in
Table 6. The implications of applying each risk test strategy to a
hypothetical population of 1,000 patients, with and without
resource constraints for actually targeting those with a positive risk
test, are also shown in Table 6. In the absence of resource
constraints, using no risk test would result in catching all eventual
cases of ART failure, and would be the preferred strategy.
However, when resource constraints are present and only half of
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be missed when only those in the high risk grouping are defined as
having a positive risk test and are targeted for services.
Secondary Analysis: ART failure by 42 months
The 42-month outcome analysis supported the findings of the
12-month analysis. Among the 441 additional patients, baseline
PDC was slightly higher than among patients in the 12-month
study (89.4% vs. 86.5%, p = 0.01), but no other patient
characteristics were significantly different. During the 42 months
after ART initiation, 376 patients (28.9%) were observed to
experience ART failure.
In the time-to-event analyses using standardized versions of the
adherence measures, PDC was again the most predictive measure
of ART failure. Kaplan-Meier survival curves stratified by the low,
medium and high risk groupings showed a higher rate of ART
failure in the high risk group compared to low and medium
groups, and the curves suggest that this relationship between
predicted risk and observed rate of failure holds even at time
points up to 3.5 years after ART initiation (Figure 3). The
difference in survival estimates among the groups was highly
statistically significant (log rank p,0.0001).
Sensitivity Analyses
Our sensitivity analyses also yielded consistent results. When
patients without baseline CD4 values were included in the 12-
month analysis, the number of included patients increased
modestly from 923 to 1,005 patients. PDC continued to be the
best-performing adherence measure. In an enriched prediction
model, hospital site emerged as an additional predictive covariate
beyond PDC, sex, baseline CD4 and pre-ART duration. Still, the
original risk score demonstrated good discrimination beyond
chance in the sensitivity analysis. Relaxing the requirement for a
Table 3. Availability of Adherence Measures during First 6 Months on ART.
Pharmacy-based measures Self-reported measures
MPR PDC TVR VAS %NoMD
n (%) n (%) n (%) n (%) n (%)
All patients (n = 2,510)
available 2,458 (97.9%) 2,458 (97.9%) 2,242 (89.3%) 1,496 (59.6%) 1,505 (60.0%)
missing 52 (2.1%) 52 (2.1%) 268 (10.7%) 1,014 (40.4%) 1,005 (40.0%)
Patients enrolled on ART before ART adherence assessment form introduced (n = 696)
available 645 (92.7%) 645 (92.7%) 589 (84.6%) 8 (1.1%) 8 (1.1%)
missing 51 (7.3%) 51 (7.3%) 107 (15.4%) 688 (98.9%) 688 (98.9%)
Patients enrolled on ART after ART adherence assessment form introduced (n = 1,814)
available 1,813 (99.9%) 1,813 (99.9%) 1,653 (91.1%) 1,488 (82.0%) 1,497 (82.5%)
missing 1 (0.1%) 1 (0.1%) 161 (8.9%) 326 (18.0%) 317 (17.5%)
MPR = Medication possession ratio; PDC = Proportion of days covered; TVR = Timely visit ratio; VAS = Visual analogue scale; %NoMD = Proportion of visits with no missed
dose reported.
doi:10.1371/journal.pone.0112261.t003
Figure 2. Baseline ART Adherence Levels (Months 1–6). Pharmacy-based measures. MPR = Medication possession ratio; sample size: n = 2,458.
PDC = Proportion of days covered; sample size: n = 2,458. TVR = Timely visit ratio; sample size: n = 2,242. Self-reported adherence measures.
VAS = Visual analogue scale; sample size: n = 1,496. %NoMD = Proportion of visits with no missed dose reported; sample size: n = 1,505. Comparison
groups. No ART failure (n = 727) and ART failure (n = 196) groups refer to patients in the primary analysis. Excluded group refers to patients excluded
from the primary analysis (n = 1,587). Overall group refers to the full population of adult ART patients (n = 2,510).
doi:10.1371/journal.pone.0112261.g002
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baseline CD4 increased the number of patients in the 42-month
analysis from 1,302 to 1,511. As in the original analysis,
stratification by risk grouping produced dramatic differences in
the Kaplan-Meier survival curves (log-rank p,0.001).
Discussion
Our study estimated that approximately one-fifth of ART
patients met the WHO immunologic or clinical criteria for ART
failure at 12 months. Pharmacy refill data, particularly the PDC
adherence measure, had high informational value in predicting
ART failure. In contrast, self-reported adherence measures were
frequently missing and, when they were captured, they offered
little value in discriminating patients who experienced ART
failure. Male sex, higher CD4 level at baseline, and less time
enrolled in care before initiating ART were also important
predictors of ART failure. A risk score based on the baseline PDC
measure together with these patient characteristics strongly
discriminated patients at risk of ART failure. Whereas only
10.1% of patients in the lowest risk score grouping experienced
ART failure, 28.7% in the highest risk score grouping did so. The
risk grouping was robust in predicting failure up to 42 months
following ART initiation, and also performed well in the context of
missing baseline CD4 results.
Our results confirm PDC to be a viable proxy for adherence.
The relative completeness of pharmacy-based data on medication
regimen types, dispense dates, and amounts of medication
dispensed, and the low likelihood that patients sought medications
from sources outside their primary facility, all support use of iSanté
pharmacy data to estimate ART adherence. Several additional
patient characteristics enriched the prediction model by reflecting
dimensions of adherence not captured in the PDC proxy measure.
For example, patients with higher baseline CD4 may have been
less motivated to consistently take the medication they had in their
possession, based upon a better overall level of health. Patients
with longer duration of pre-ART enrollment may have included
those who are inherently likely to remain in care and comply with
recommended care behaviors (since others may have dropped out
before initiating ART), while patients with brief duration of pre-
ART enrollment may have included patients with a mix of
inherent tendencies toward compliance. Lower pre-ART duration
has been identified as a risk factor for ART attrition in Haiti [30].
The higher risk of ART failure we found among males is consistent
with evidence of elevated ART attrition risk among males in Haiti
and elsewhere in the Caribbean region [31].
In a resource-limited setting like Haiti, our risk score has an
important role to play in helping providers target patients for
adherence support services before ART failure occurs. Such
services could include in-depth counseling sessions with social
workers or psychologists, adherence reminder phone calls or text
messages, outreach visits by community health workers, or other
supportive interventions. In the context of highly constrained
human and material resources, it may not be possible to offer these
interventions on a universal basis. This reality is underscored by
the fact that nearly 20% of patients in our study population had no
adherence assessment and counseling form completed. That these
very patients tended to have lower adherence levels by pharmacy-
based refill data, indicates that providers seemed to be missing
patients with high levels of need. When resources are constrained,
using the information about which patients are at higher risk of
ART failure could help to decrease the number of eventual cases
of ART failure which are missed. In a hypothetical cohort of 1,000
ART patients of whom only half can be reached with intensive
adherence support services, targeting these services to high risk
patients would result in missing 40% fewer of these critical cases.
Even if universal coverage with adherence support interventions
is possible, knowing a patient’s risk grouping could still help
providers customize their communication messages according to
risk grouping. For example, counseling for a patient at lower risk
could focus on reinforcing positive behaviors. For those at higher
risk, counseling could focus on identifying and overcoming
barriers to adherence and could include referrals to other intensive
adherence support services. This type of targeted communication
strategy is identified as a best practice in HIV adherence support
[32].
The first recommendation arising from our study is to use the
validated risk scoring algorithm to program an automated
provider alert within the iSanté electronic medical record system.
The alert could be used in either an active or passive manner. For
an iSanté alert to be successful, providers would need to receive
training on how to interpret the alert and integrate its use within
their care delivery processes. Well-designed electronic clinical
alerts and reminders have been shown to improve quality of care
and patient health outcomes [33,34,35,36,37].
The second recommendation arising from our study is to drop
routine, universal documentation of self-reported adherence
measures by providers. Leveraging automated adherence estimates
derived from pharmacy refill data would allow for more efficient
use of health worker and patient time, eliminating the need for
providers to collect and record self-reported adherence data for
patients with already-strong adherence by pharmacy data.
Pharmacy personnel, who were responsible for completing about
half of the adherence assessments for patients in our study, could
shift their attention toward assuring strong data quality in the
pharmacy dispense and refill data, as well as toward following up
with patients who are late for pharmacy refills. Having providers
ask patients about adherence levels and barriers could have value
as a cue to favorable adherence behaviors among patients; so it is
Table 4. Performance of Baseline Adherence Measures as Predictors of ART Failure at 12 Months.
Measure Functional form n AUC 95% CI
MPR continuous 899 0.60 (0.56, 0.65)
PDC continuous 899 0.61 (0.56, 0.66)
TVR continuous 875 0.56 (0.52, 0.61)
%NoMD continuous 583 0.52 (0.46, 0.57)
VAS continuous 582 0.50 (0.44, 0.56)
MPR: Medication possession ratio; PDC: Proportion of days covered; TVR: Timely visit ratio; VAS: Visual analogue scale; %NoMD: Proportion of visits with no missed dose
reported; AUC: Area under the receiver operating curve; CI: confidence interval.
doi:10.1371/journal.pone.0112261.t004
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important to note that the recommendation is not to abandon
these conversations but rather to drop universal data collection of
the self-reported adherence measures.
Strengths and Limitations
A strength of our study is the exploration of several types of
adherence measures in order to identify the measure which
performed best in predicting ART failure. Another strength is that
in evaluating various prediction models, we looked for a balance
between the simplicity of the model and the robustness of its
statistical performance. For an automated alert to be effective in
Haiti, it is important that it be well-understood and trusted by
Haitian providers. Our four-factor model, using binary thresholds
for PDC, baseline CD4, and pre-ART duration, can be easily
understood as representing a common ‘‘profile’’ of patients at high
risk of ART failure. The risk groupings with low, medium, and
high categories are also intuitive. A final strength of our study is
the use of a randomly split sample in developing and validating the
risk score. The strong performance of the risk score and risk
grouping within the validation sample speaks favorably to the
generalizability of our results to other patient populations and at
other sites.
A key limitation of our study is the fact that many patient
records lacked either baseline or follow-up CD4 values, meaning
they lacked data on the ART failure outcome. Both our secondary
and our sensitivity analyses supported the primary findings when
including patients with follow-up CD4 results only available after
12 months and patients with no baseline CD4 results. Further, the
distribution of sex and the average levels of baseline CD4 and pre-
ART duration did not differ between patients included vs.
excluded from the primary analysis. This gives modest evidence
for the generalizability of our findings to patients who were
excluded from the primary analysis.
A second concern related to generalizability of our findings is
that our study examined ART patients from only two facilities,
representing approximately 6% of all ART patients within the
iSanté data system. ART patients at HSA and HSM may be
different from patients in other sites. Other iSanté sites might not
share the relatively high completeness of pharmacy data we found
in our cohort. Other sites may also have implemented the self-
reported adherence assessments in a different manner, rendering
the information more useful.
A third limitation of our study is that AUC values of above 0.70
are typically considered desirable for screening and diagnostic
tests. An algorithm for ART failure risk developed for several
large-scale electronic medical record systems in Boston demon-
strated an AUC of 0.78, indicating strong discrimination [38].
ART adherence measures in South Africa had AUC values of
0.67–0.74 in predicting virologic failure at 6 or 12 months [39].
Our study found slightly lower AUC values, indicating weaker
ability to discriminate ART failures from non-failures. Still, our
risk score grouping was notably better than chance in predicting
ART failure and would be useful in targeting patients, particularly
since no harmful procedures would be triggered by false positive
results of the risk test.
HIV viral load testing, the ‘‘gold standard’’ measure of ART
failure, is not widely available in Haiti. There can be substantial
misclassification of ART failure status when only immunologic
and clinical status is known and no confirmatory viral load testing
is available [40,41,42,43]. Still, the WHO immunologic and
clinical criteria for ART failure represent the available information
upon which clinicians in Haiti must act. If viral load becomes
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the study methodology to validate a simple and robust prediction
model for this ‘‘gold standard’’ outcome.
Several important patient-level factors which might be impor-
tant predictors of ART adherence and ART failure — such as
employment status, socioeconomic status, food security, level of
education, mental health status, drug and alcohol use, pill burden,
and concurrent treatments with potential for drug interactions and
additional side effects — were also not available within iSanté or
were not available for the purposes of the study. Data on timing
and frequency of ART stock-outs at the health facilities were also
unavailable. Whether patients were infected with drug-resistant
strains of HIV before initiating ART was also unknown, due to the
Table 6. Diagnostic ‘‘Risk Test’’ Characteristics under Different Strategies.
Low + medium + high groups have
positive ‘‘risk test’’ (no ‘‘risk test’’)
Medium + high groups have
positive ‘‘risk test’’
High group has positive
‘‘risk test’’
Test classification characteristics
Sensitivity 100.0% 89.6% 70.8%
Specificity 0.0% 24.4% 53.7%
PPV 20.8% 23.8% 28.7%
NPV NA 89.9% 87.5%
Correctly classified 20.8% 38.0% 57.3%
Hypothetical population of 1,000 with unlimited resources for targeting
Total targeted 1000 785 514
Cases of failure among targeted 208 186 147
Cases of non-failure among
targeted
792 599 367
Cases of failure missed 0 22 61
Hypothetical population of 1,000 but with resources to target only 500
Total targeted 500 500 500
Cases of failure among targeted 104 119 143
Cases of non-failure among
targeted
396 381 357
Cases of failure missed 104 89 65
PPV = positive predictive value; NPV = negative predictive value.
doi:10.1371/journal.pone.0112261.t006
Figure 3. Kaplan Meier Curves for ART Failure by Risk Category (42-month outcome). Log rank test: p,0.001; CI: Confidence interval.
doi:10.1371/journal.pone.0112261.g003
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lack of routine drug susceptibility testing. In the only published
study on ART drug resistance in Haiti, 40% of urban adolescents
were found to have drug resistance after 12 months on ART [44],
indicating the potential for concerning circulation of drug-resistant
strains of HIV in the population.
Conclusions
There is a critical need to support high ART adherence among
patients placed on first-line ART regimens in resource-limited
settings, to avoid cases of ART failure. Electronic medical record
systems like iSanté can return relevant, actionable information to
clinicians so that they can identify patients with problematic
adherence and high risk of ART failure. Our study results support
the development of an automated alert, leveraging iSanté
pharmacy refill data as well as other patient characteristics, to
predict risk of ART failure before it occurs. Such an alert could
help in targeting patients with greatest need for in-depth ART
adherence counseling and other supportive services. It would also
help providers customize counseling messages according to the
patient’s level of risk. In the context of limited resources, there is
high informational value in an alert which can improve targeting
of patients in these ways.
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